Tilelizumab Combined With Nab-Paclitaxel for High-Risk Non-Muscle-Invasive Urothelial Bladder Carcinoma Which is Not Completely Resectable: a Multi-center Study
Clinical trial NCT05418309 · UNKNOWN
Trial details
- NCT number
- NCT05418309
- Sponsor
- Tianjin Medical University Second Hospital
- Status
- UNKNOWN
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2021-12-27
- Primary completion
- 2024-02-01
- Enrollment
- 63
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.